Dynamic Technology Lab Private Ltd Invests $831,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dynamic Technology Lab Private Ltd purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 13,408 shares of the medical equipment provider’s stock, valued at approximately $831,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Norges Bank acquired a new position in Lantheus during the 4th quarter worth $29,956,000. First National Advisers LLC lifted its holdings in Lantheus by 47.3% in the fourth quarter. First National Advisers LLC now owns 19,180 shares of the medical equipment provider’s stock worth $1,189,000 after purchasing an additional 6,160 shares during the period. Navellier & Associates Inc. grew its position in Lantheus by 13.9% in the 4th quarter. Navellier & Associates Inc. now owns 19,191 shares of the medical equipment provider’s stock valued at $1,190,000 after buying an additional 2,337 shares in the last quarter. Torray Investment Partners LLC increased its stake in Lantheus by 1.7% during the 4th quarter. Torray Investment Partners LLC now owns 24,316 shares of the medical equipment provider’s stock valued at $1,508,000 after buying an additional 396 shares during the period. Finally, Janney Montgomery Scott LLC raised its position in shares of Lantheus by 6.2% during the 4th quarter. Janney Montgomery Scott LLC now owns 8,005 shares of the medical equipment provider’s stock worth $497,000 after buying an additional 467 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now owns 62,898 shares in the company, valued at approximately $4,836,227.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 94,545 shares of company stock worth $6,177,295. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on LNTH. B. Riley increased their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Mizuho upped their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Truist Financial raised their target price on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, JMP Securities reiterated a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.17.

Check Out Our Latest Research Report on LNTH

Lantheus Trading Up 0.8 %

NASDAQ:LNTH opened at $81.35 on Thursday. The stock has a fifty day simple moving average of $66.43 and a 200 day simple moving average of $63.86. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $5.64 billion, a price-to-earnings ratio of 12.42 and a beta of 0.52. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.48.

Lantheus (NASDAQ:LNTHGet Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The business had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Further Reading

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.